Executive turnover reflects changing drug industry

11/1/2007 | Financial Times (free content)

The appointment of new chief executives at GlaxoSmithKline, Sanofi-Aventis and other major drug companies indicates that big pharma is struggling to recover from slumping valuations and competition from generics. Firms are also tapping young leaders, focusing on the international market, appointing executives with little background in research and development, and selecting from within rather than recruiting outside executives.

View Full Article in:

Financial Times (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD